Mesenchymal stem cells versus mesenchymal stem cells-derived exosomes as potential autophagy pathway modulators in a diabetic model

Fatma Y. Meligy, Hanan Sharaf El Deen Mohammed, Amal T. Abou Elghait, Heba K. Mohamed, Israa El Sayed Mohamed Ashry, Ayat Abdel-Rahman Sayed, Ola A. Hussein, Ahmed Salman, Tarek Atia, Abir S. Mohamed, Nour H. Behnsawy, Safy Salah Gaber, Hader I. Sakr, Salwa Fares Ahmed

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: This work compared the potential effects of bone marrow mesenchymal stem cells (BM-MSCs) with BM-MSCs-derived exosomes against impaired autophagy in streptozotocin (STZ)-induced diabetic rats. Materials and methods: Three days after STZ injection, a single dose of (3 ​× ​10^6) BM- MSCs or BM-MSCs-derived exosomes (80 μg/rat) was administered to evaluate their effects against nondiabetic and diabetic control rats. We assessed pancreatic structure via light and electron microscopy and evaluated its staining for insulin and the autophagy marker P62 immunohistochemically. Moreover, autophagy marker LC3 gene expression was examined by PCR. Results: Both BM-MSCs and BM-MSCs derived exosomes showed histological restoration of pancreatic tissues. Both treatments markedly increased the amount of insulin and significantly decreased the autophagy markers P62 and LC3. Conclusion: Our findings suggest that both BM-MSCs and BM-MSCs-derived exosomes provides a potential alternative to modulate diabetes mellitus.

Original languageEnglish
Pages (from-to)152-165
Number of pages14
JournalAdvances in Medical Sciences
Volume70
Issue number1
DOIs
StatePublished - Mar 2025

Keywords

  • Autophagy
  • Diabetes mellitus
  • Exosome
  • Mesenchymal stem cells

Fingerprint

Dive into the research topics of 'Mesenchymal stem cells versus mesenchymal stem cells-derived exosomes as potential autophagy pathway modulators in a diabetic model'. Together they form a unique fingerprint.

Cite this